conception of a diagnosis, prognosis and therapeutic decision tool for patients with autoimmunity and inflammation

Conditions: Autoimmune Lymphoproliferative Syndrome; Autoimmune Cytopenia; Autoimmune Diseases; Autoimmune Anemia; Autoimmune Thrombocytopenia; Autoimmune Hepatitis; Autoimmune Diabetes; Autoimmune Rheumatologic Disease; Systemic Lupus Erythematosus; Juvenile Idiopathic Arthritis; Hemophagocytic Lymphohistiocytoses; EBV Lymphoproliferation; RAS-Associated Autoimmune Leucoproliferative Disease; Primary Immunodeficiency; APECED; IPEX; BENTA; Enteropathy, Autoimmune; Combined Immunodeficiency; IBD

Summary: the main objective of this study is to generate diagnosis and therapeutic-decision tools through the identification of molecular causes of pids with autoimmunity/inflammation and the variability in disease outcome at the transcriptional level using a combination of omics signatures (transcriptomics, epigenomics, proteomics, metagenomics, metabolomics and lipidomics).

primary immune deficiencies (pids) are a group of monogenic diseases related to developmental or functional dysfunction of one or several immune cell types. individually there are rare entities, but collectively they group several thousands of patients. approximately 500 000 patients suffer from pids worldwide, making their management a true health-care concern. according to european society for immunodeficiencies (esid), the age group in which pids is most frequently diagnosed is under 19 years of age (62%)1. pids are causing susceptibility to severe and life-threatening infections by common pathogens, but they also predispose to cancer and can initially manifest as autoimmune and inflammatory diseases. multiple mechanisms underlie the development of autoimmunity/inflammation in pids. moreover, their development can be influenced by the composition of the microbiota, which shapes host metabolic and immune functions and can be modified by many environmental factors. in the last two decades a particular emphasis was given to the elucidation of the genomic mutations causing pids. this led to a burst of genetic diagnosis as the numbers of known monogenic causes of pids rose from around 200 in 2010 to more than 310 in 2017. these genomic approaches revealed that: 1) a given monogenic defect can lead to very dissimilar clinical presentations, disproving the initial concept that a monogenic defect is associated with specific clinical manifestations ; and 2) the number of cases of autosomal dominant genetic deficiencies has increased, with sometimes a partial clinical penetrance so that some relatives carrying the causal genetic variant remain asymptomatic. hence, onset and presentation of autoimmune and inflammatory diseases in pids is highly unpredictable. pids with autoimmunity/inflammation usually require life-long symptomatic treatments including broad immunosuppression or immunotherapies. on the long term, such treatments can have important side effects or poor efficacy and they result in high burden cost. it is therefore crucial to diagnose pids as early as possible in order to select the most efficient therapy based not only on clinical features as it is nowadays, but to include the underlying molecular cause of immune dysregulation. the central goal of this project is to explain the very variable outcome of monogenic autoimmune and inflammatory diseases and to define predictive biomarkers in order to stratify patients and to optimize therapeutic choices.

Eligibility criteria:
inclusion criteria for controls (patients relatives and unrelated subjects): * individuals aged\<18 y/o. * individuals \> 6 kg * individuals not affected by an immune-related disease or not affected by cancer * individuals whose parents have signed an enlightened consent. inclusion criteria for patients * individuals with health insurance. * patients treated at necker hospital with pids and autoimmunity/inflammation related to known genetic defects (cytopenia, enteropathy inflammatory bowel disease (ibd), systemic lupus erythematosus (sle), juvenile idiopathic arthritis (jia), familial hemophagocytic lymphohistiocytosis (fhl), chronic ebv infection associated (ca-ebv) with ebv-infected t and/or natural killer (nk) cells and with a high risk to develop macrophage activation syndrome similar to fhl. see table below for diagnosis inclusion criteria. * individuals aged\<18 y/o. * individuals \> 9 kg * patients whose parents have signed an enlightened consent. exclusion criteria: * intake of antibiotics within 2 weeks prior inclusion * absence of parent's or child consent form * cytotoxic cancer treatments * antiviral treatments (hiv, hepatitis ...) * short term life-threatening conditions * individuals placed under judicial protection